InflaRx N.V. (NASDAQ:IFRX) Receives Average Rating of “Moderate Buy” from Brokerages

InflaRx N.V. (NASDAQ:IFRX) has been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $7.50.

A number of brokerages have issued reports on IFRX. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of InflaRx in a research report on Tuesday, December 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a report on Monday, December 29th. Guggenheim raised their target price on shares of InflaRx from $10.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Leerink Partners restated a “market perform” rating and set a $2.00 price target (down from $5.00) on shares of InflaRx in a research report on Wednesday, December 3rd. Finally, Leerink Partnrs cut shares of InflaRx from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 3rd.

Hedge Funds Weigh In On InflaRx

Several hedge funds have recently modified their holdings of IFRX. Cubist Systematic Strategies LLC raised its stake in shares of InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after buying an additional 7,616 shares in the last quarter. Woodline Partners LP bought a new position in InflaRx during the first quarter valued at about $766,000. Concurrent Investment Advisors LLC acquired a new position in InflaRx during the second quarter worth about $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in InflaRx by 158.3% in the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock worth $118,000 after acquiring an additional 91,927 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in InflaRx in the 2nd quarter valued at about $262,000. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Trading Down 4.6%

Shares of NASDAQ:IFRX opened at $1.04 on Friday. The firm’s 50 day moving average is $1.16 and its two-hundred day moving average is $1.14. The firm has a market capitalization of $69.82 million, a P/E ratio of -1.53 and a beta of 1.44. InflaRx has a 52 week low of $0.71 and a 52 week high of $2.77.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. Analysts predict that InflaRx will post -1.04 EPS for the current year.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.